Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, ...

Doctors are continuing to issue warnings regarding the illicit use of Ozempic, Wegovy and Mounjaro as weight loss injections, ...

Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug ...

Fintech-focused NBFC UGRO Capital has approved the final terms for its much-awaited rights issue. The company will raise up ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

Clairity has received U.S. FDA De Novo authorization for CLAIRITY BREAST, a prognostic platform designed to predict five-year ...

Doctors have warned users of medicines such as Ozempic Wegovy and Mounjaro about an irreversible potential side effect ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...

Biocon is gearing up to become a dominant player in the diabetes and obesity drug market. This comes as the pharma world ...

Sail Biomedicines, a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that it will present new preclinical data from its malaria vaccine program at the 2025 ...

Acxiom, the connected data and technology foundation for the world's leading brands, today announced RafterOne is now part of the Acxiom Salesforce Practice. This integration combines Acxiom's ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...